36.34

0.03% 0.01

Pacira Biosciences Inc (PCRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$36.33

Aprire:

$36.38

Volume 24 ore:

960.89K

Relative Volume:

0.21

Capitalizzazione di mercato:

$1.45B

Reddito:

$734.86M

Utile/perdita netta:

$5.14M

Rapporto P/E:

290.72

EPS:

0.125

Flusso di cassa netto:

$132.71M

1 W Prestazione:

+0.08%

1M Prestazione:

+45.89%

6M Prestazione:

+52.31%

1 anno Prestazione:

+59.60%

Intervallo 1D:

$36.32

$36.39

Intervallo di 1 settimana:

$36.30

$36.66

Portata 52W:

$18.80

$36.66

Pacira Biosciences Inc Stock (PCRX) Company Profile

Nome

Pacira Biosciences Inc

Settore

Healthcare (1052)

Industria

Drug Manufacturers - Specialty & Generic (84)

Telefono

650-242-8052

Indirizzo

2000 SIERRA POINT PARKWAY, BRISBANE, NJ

Dipendente

829

Cinguettio

Prossima data di guadagno

2026-11-05

Ultimi documenti SEC

PCRX's Discussions on Twitter

Compare PCRX vs TAK, TEVA, HLN, ZTS, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
PCRX Pacira Biosciences Inc	36.34	1.45B	734.86M	5.14M	132.71M	0.125
TAK Takeda Pharmaceutical Co Adr	19.67	62.84B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	41.50	48.40B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	10.13	44.55B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	79.38	32.80B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	533.12	22.87B	3.17B	1.29B	1.01B	27.09

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-09-23	Iniziato	Oppenheimer	Outperform
2026-09-09	Iniziato	Leerink Partners	Market Perform
2026-08-17	Ripresa	Truist	Buy
2025-12-09	Iniziato	Barclays	Equal Weight
2025-11-17	Iniziato	H.C. Wainwright	Buy
2025-07-25	Aggiornamento	Truist	Hold → Buy
2025-01-30	Aggiornamento	Truist	Sell → Hold
2024-08-13	Downgrade	Truist	Buy → Sell
2024-08-12	Downgrade	JP Morgan	Overweight → Underweight
2024-08-12	Downgrade	Piper Sandler	Overweight → Neutral
2024-08-12	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2024-08-12	Downgrade	Raymond James	Outperform → Mkt Perform
2024-07-03	Downgrade	Barclays	Overweight → Equal Weight
2024-03-07	Ripresa	JP Morgan	Overweight
2023-12-20	Iniziato	Raymond James	Outperform
2023-08-03	Aggiornamento	TD Cowen	Market Perform → Outperform
2023-01-31	Ripresa	Wedbush	Outperform
2022-10-21	Ripresa	Jefferies	Buy
2022-01-03	Ripresa	JP Morgan	Overweight
2021-07-26	Aggiornamento	JP Morgan	Neutral → Overweight
2021-04-21	Ripresa	JP Morgan	Neutral
2021-04-09	Iniziato	Berenberg	Buy
2021-04-07	Ripresa	RBC Capital Mkts	Outperform
2021-02-11	Downgrade	Northland Capital	Outperform → Market Perform
2021-01-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
2020-09-21	Aggiornamento	Northland Capital	Market Perform → Outperform
2020-07-06	Reiterato	Needham	Buy
2020-05-27	Iniziato	Guggenheim	Neutral
2020-04-07	Iniziato	Northland Capital	Outperform
2020-03-20	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2020-02-24	Reiterato	H.C. Wainwright	Buy
2020-01-24	Iniziato	SunTrust	Buy
2020-01-23	Iniziato	SunTrust	Buy
2019-11-06	Iniziato	BTIG Research	Buy
2019-06-11	Iniziato	Barclays	Overweight
2019-05-06	Aggiornamento	Mizuho	Underperform → Neutral
2019-05-02	Aggiornamento	Stifel	Sell → Hold
2019-02-01	Downgrade	Mizuho	Neutral → Underperform
2018-08-06	Downgrade	BofA/Merrill	Buy → Neutral
2018-04-09	Reiterato	H.C. Wainwright	Buy
2018-03-21	Reiterato	Mizuho	Neutral
2018-02-16	Downgrade	Needham	Buy → Hold
2018-01-19	Iniziato	Seaport Global Securities	Buy
2018-01-04	Reiterato	Canaccord Genuity	Buy
2018-01-03	Iniziato	Leerink Partners	Mkt Perform

Mostra tutto

Pacira Biosciences Inc Borsa (PCRX) Ultime notizie

Oct 13, 2026

Seven investors report stakes below 5% in Pacira BioSciences (PCRX). - Stock Titan

Oct 13, 2026

Oct 12, 2026

Form 4 Pacira Pharmaceuticals Inc For: 12 October By Investing.com - Investing.com South Africa

Oct 12, 2026

Pacira BioSciences SVP Riker sells $217,920 stock - Investing.com

Oct 12, 2026

Pacira BioSciences SVP Riker sells $217,920 stock By Investing.com - Investing.com Canada

Oct 12, 2026

Oct 11, 2026

Pacira BioSciences SVP Lauren Riker sells $217,920 in stock - Investing.com

Oct 11, 2026

Form 4 Pacira Pharmaceuticals Inc For: 10 October By Investing.com - Investing.com South Africa

Oct 11, 2026

Oct 10, 2026

Pacira BioSciences SVP Lauren Riker sells $217,920 in stock - Investing.com

Oct 10, 2026

Oct 09, 2026

Form 4 Pacira Pharmaceuticals Inc For: 9 October By Investing.com - Investing.com South Africa

Oct 09, 2026

Pacira BioSciences senior vice president Lauren Riker sells $217,920 in stock By Investing.com - Investing.com South Africa

Oct 09, 2026

Form 4 Pacira Pharmaceuticals Inc For: 9 October By Investing.com - Investing.com Nigeria

Oct 09, 2026

Pacira BioSciences senior vice president Lauren Riker sells $217,920 in stock - Investing.com

Oct 09, 2026

After exercising options, Lauren Riker sells 6,000 Pacira BioSciences (PCRX) shares. - Stock Titan

Oct 09, 2026

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - Zacks Investment Research

Oct 09, 2026

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - TradingView

Oct 09, 2026

Oct 08, 2026

An offer for all Pacira BioSciences (PCRX) shares is planned but has not yet begun. - Stock Titan

Oct 08, 2026

No financing condition applies to the planned Viatris takeover of Pacira BioSciences (PCRX). - Stock Titan

Oct 08, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Oct 08, 2026

Pacira BioSciences (Nasdaq: PCRX) Makes 52 Week High on Acquisition News - Investorideas.com

Oct 08, 2026

Viatris Inc. entered into a definitive agreement to acquire Pacira BioSciences, Inc. for $1.6 billion. - marketscreener.com

Oct 08, 2026

Viatris to Acquire Pacira BioSciences for $36.50 Per Share in $1.65 Billion Cash Deal - Minichart

Oct 08, 2026

Why Pacira BioSciences Skyrocketed Today - The Motley Fool

Oct 08, 2026

Viatris Acquires Pacira BioSciences for $1.65 Billion - Pharmaceutical Executive

Oct 08, 2026

A 6,000-share sale is proposed by Lauren B. Riker of Pacira BioSciences (PCRX). - Stock Titan

Oct 08, 2026

With unanimous board backing, Pacira (PCRX) agrees to an all-cash Viatris takeover. - Stock Titan

Oct 08, 2026

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies - Viatris Newsroom

Oct 08, 2026

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies - PR Newswire

Oct 08, 2026

Oct 06, 2026

PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal - Zacks Investment Research

Oct 06, 2026

Oct 05, 2026

Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom - Orthopedics This Week

Oct 05, 2026

A postsurgery pain medicine is planned to launch in four countries; first sales are expected in 2027. - Stock Titan

Oct 05, 2026

Sep 12, 2026

Discipline and Rules-Based Execution in PCRX Response - Stock Traders Daily

Sep 12, 2026

Sep 11, 2026

Pacira Biosciences (NASDAQ:PCRX): An Undervalued Value Stock Backed by Cash Flow and Balance Sheet Strength - ChartMill

Sep 11, 2026

PACIRA BIOSCIENCES, INC. : LEERINK PARTNERS INITIATES COVERAGE WITH MARKET PERFORM RATING; PRICE TARGET $28 - webull.com

Sep 11, 2026

Sep 09, 2026

PCRX Initiated Coverage by Leerink Partners -- Rating Market Per - GuruFocus

Sep 09, 2026

Five new employees receive Pacira stock awards, vesting over four years - Stock Titan

Sep 09, 2026

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 09, 2026

Sep 03, 2026

Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Sep 03, 2026

Sep 02, 2026